Formycon mit Sitz in Martinsried bei München entwickelt biopharmazeutische Nachahmerprodukte für die Zulassung in Europa, USA und Japan. Biopharmazeutika (Antikörper) werden bei Krebs eingesetzt.

COMPANY

Formycon

INVESTOR TERMSHEET

#BGFL app

#BGFL Publisher

FYB

Formycon

#BGFL Mood: Neutral · #BGFL-Indicator: Hold · Review date: -

LEI: 39120005TZ76GQOY8Z19

SECTOR: Gesundheit SUB-SECTOR: Biotechnologie

NAME

Formycon

WKN

A1EWVY

ISIN

DE000A1EWVY8

TICKER

FYB

INDEX

SDAX

EXCHANGE

Xetra

BUY SELL

Made with ❤ von BGFL

#BGFL

Newswire

Ratings

#BGFL-nes Formycon: boersengefluester.de (BGFL) regularly writes extensive editorial articles for most of the companies in our database - especially those in the special stocks sector. Here we show you a list of the most recent articles by BGFL on the selected share.

19.12.2017	Formycon: Nachahmung empfohlen
27.03.2014	Formycon: Unangenehme Kursschwankungen

Newswire Formycon: Official company news is an enormously important source of information for investors - especially if it is particularly price-sensitive and therefore subject to ad hoc disclosure. Here we show the reports provided by the IR portal EQS News on companies from the BGFL coverage universe.

09.12.2024	EQS-News: MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region
05.12.2024	EQS-News: Formycon joins the SDAX of the German Stock Exchange
28.11.2024	EQS-News: Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes
19.11.2024	EQS-News: Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
18.11.2024	EQS-News: Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®

Resaerch for Formycon: Independent research is hard to find, especially in the speciality stocks sector. However, there are a number of firms that regularly produce meaningful analyses of the companies they cover. As a rule, this is paid research - but the analyses are definitely worth reading.

11.12.2024	Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
01.10.2024	Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
19.08.2024	Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
13.06.2024	Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy

The #BGFL Coverage App Gallery

Visualisation of financial information has been one of boersengefluester.de's (BGFL) favourite disciplines from the very beginning. For this reason, we also put a lot of effort into maintaining our own database and have developed numerous analysis tools and key figure tables on this basis.

Corporate Name Change

Financial Calendar

Interviews, Quotes, Analyses

IR-Quick Check

Annual Reports

Does news drive share prices or does the chain of effects run the other way round - as is often assumed? Well, at boersengefluester.de we offer you all kinds of ways to follow daily stock market events. Take a look at our apps on the subject of news.

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.

Formycon

Quick Links

Network

Partner

Contact

Formycon

Would you like to see fewer adverts? Simply register for a user account. Registration is free and significantly reduces the number of adverts.

Quick Links

Network

Partner

Contact